Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika to Participate in Upcoming Investor Conferences
BEDFORD, Mass. , Nov. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard , President and Chief Executive Officer and Michael Levitz , Executive Vice President, Chief
View HTML
Toggle Summary Anika Reports Third Quarter 2021 Financial Results
Revenue growth of 25% year-over-year Company revises revenue growth outlook for 2021 to 9-11% on COVID Delta headwinds BEDFORD, Mass. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported
View HTML
Toggle Summary Anika Appoints Sheryl Conley to Board of Directors
Appointment brings experienced orthopedic industry commercial leader to Anika’s Board BEDFORD, Mass. , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of
View HTML
Toggle Summary Anika to Issue Third Quarter 2021 Financial Results on Thursday, November 4, 2021
BEDFORD, Mass. , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2021 financial results after the close of the market on Thursday,
View HTML
Toggle Summary Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting
Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion BEDFORD, Mass. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.
View HTML
Toggle Summary Tactoset® Injectable Bone Substitute Now FDA Cleared for Hardware Augmentation
510(k) clearance expands the capability of Tactoset for augmenting suture anchor fixation BEDFORD, Mass. , Sept. 14, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received
View HTML
Toggle Summary Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
BEDFORD, Mass. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that Dr. Cheryl Blanchard , President and Chief Executive Officer and Michael Levitz , Executive Vice
View HTML
Toggle Summary Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting
Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation market BEDFORD, Mass. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on
View HTML
Toggle Summary Anika Reports Second Quarter 2021 Financial Results
Revenue growth of 24% year-over-year Company raises full year revenue growth outlook to 11-14% BEDFORD, Mass. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its
View HTML
Toggle Summary Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021
BEDFORD, Mass. , July 19, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2021 financial results after the close of the market on Thursday,
View HTML